Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352859 · ClinicalTrials.gov registry record · Phase 4
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
A Phase 4 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00352859 is a Phase 4 study that was terminated before completion, run by Bayer. The registered enrollment target is 2 participants.
The verdict
NCT00352859, a Phase 4 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to see if taking interferon or gemcitabine along with sorafenib will stop the advanced renal cell cancer from becoming worse in some people. To do this, sorafenib along with gemcitabine or interferon will be compared to treatment with gemcitabine or interferon alone. More safety information on sorafenib will be also collected. About 260 patients with progressed renal cell cancer will be in this study.
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon
- DRUG Gemcitabine or Interferon (only)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-08 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352859
The ClinicalTrials.gov registry entry for NCT00352859 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon is the first listed.
NCT00352859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352859 about?
NCT00352859 is a clinical study titled "Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib". The purpose of this study is to see if taking interferon or gemcitabine along with sorafenib will stop the advanced renal cell cancer from becoming worse in some people. To do this, sorafenib along with gemcitabine or interferon will be compared to treatment with gemcitabine or interferon alone. Mor...
What is the current status of trial NCT00352859?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2006-08. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00352859?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon (DRUG), Gemcitabine or Interferon (only) (DRUG).
Who is sponsoring clinical trial NCT00352859?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.